Investment analysts at Piper Sandler began coverage on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) in a research report issued to clients and investors on Friday, The Fly reports. The firm set an “overweight” rating on the biotechnology company’s stock.
IRWD has been the subject of a number of other research reports. TheStreet upgraded Ironwood Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, January 19th. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, April 1st. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $14.33.
Shares of IRWD stock opened at $11.78 on Friday. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 3.65 and a beta of 1.22. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.61 and a quick ratio of 4.61. The business has a fifty day moving average of $11.84 and a 200 day moving average of $11.89. Ironwood Pharmaceuticals has a 1 year low of $10.13 and a 1 year high of $14.27.
In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 3,031 shares of the business’s stock in a transaction that occurred on Thursday, March 24th. The stock was sold at an average price of $12.75, for a total value of $38,645.25. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.60% of the stock is currently owned by insiders.
Several large investors have recently bought and sold shares of IRWD. Point72 Hong Kong Ltd acquired a new position in shares of Ironwood Pharmaceuticals in the third quarter worth $43,000. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth $63,000. C M Bidwell & Associates Ltd. acquired a new position in shares of Ironwood Pharmaceuticals during the third quarter worth $83,000. Advisor Group Holdings Inc. grew its stake in shares of Ironwood Pharmaceuticals by 267.6% during the third quarter. Advisor Group Holdings Inc. now owns 8,143 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 5,928 shares in the last quarter. Finally, Financial Counselors Inc. acquired a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth $117,000.
About Ironwood Pharmaceuticals (Get Rating)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- Should You Buy Carvana or AutoNation or Pass on Both?
- What Should Investors Take Away From Boston Beer’s Earnings?
- High-Yield Kinder Morgan Is Still A Buy
- NextEra Energy Offers a Long-Term Gain if You Can Tolerate Short-Term Pain
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.